Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $27.05, but opened at $26.00. Ascentage Pharma Group International shares last traded at $26.00, with a volume of 1,242 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. BTIG Research began coverage on shares of Ascentage Pharma Group International in a research note on Monday, November 10th. They set a “buy” rating and a $50.00 price objective on the stock. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. Piper Sandler assumed coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 target price for the company. Finally, Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Trading Down 1.2%

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The firm has a 50 day simple moving average of $29.46 and a two-hundred day simple moving average of $35.53.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several institutional investors have recently added to or reduced their stakes in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $96,000. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the third quarter worth $204,000. Chevy Chase Trust Holdings LLC purchased a new position in shares of Ascentage Pharma Group International in the second quarter valued at $227,000. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at $383,000. Finally, Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter worth about $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.